-+ 0.00%
-+ 0.00%
-+ 0.00%
Impact Biomedical completes merger, becomes wholly owned subsidiary of PubCo
Share
Listen to the news
Impact Biomedical completes merger, becomes wholly owned subsidiary of PubCo
  • Impact Biomedical became a wholly owned subsidiary of PubCo on November 17, 2026, following its merger with Merger Sub.
  • PubCo also acquired all outstanding ordinary shares of Zoar, making it a wholly owned subsidiary.
  • Impact shareholders received 8,640,000 PubCo ordinary shares, representing approximately 4.8% of PubCo's outstanding ordinary shares at closing.
  • Each Impact common share converted into one PubCo ordinary share following a 1-for-12.62 reverse stock split.
  • Shareholders had approved the transaction on November 13, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Impact Biomedical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-053017), on November 18, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending